GlassScriptPhysician profile
Sherrie Irvine Smith
NPI 1932773678
$4,242.62
in general payments reported to CMS, 2019-2025
19 companies · $1,421 in 2025
The $1,421 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.82 · 2023: $1,570 · 2024: $1,226 · 2025: $1,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,216.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $546.59 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $526.85 | 2023-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $505.21 | 2023-2024 | Rexulti, Nuedexta, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $339.72 | 2023-2025 | Caplyta |
| Lundbeck LLC | $324.80 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $308.91 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $292.59 | 2023-2025 | Trintellix |
| Axsome Therapeutics, INC. | $248.75 | 2023-2025 | Auvelity |
| Abbvie INC. | $238.82 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $221.03 | 2024-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $199.14 | 2023-2024 | Jornay Pm |
| Alkermes, INC. | $188.75 | 2023-2025 | Lybalvi, Aristada, Vivitrol |
| Indivior INC. | $77.12 | 2024 | Sublocade |
| Biogen, INC. | $73.43 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $52.09 | 2023 | Quviviq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.32 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $28.78 | 2025 | Qelbree |
| Tempus Ai, INC | $22.56 | 2025 | Xt Cdx |
| Noven Therapeutics, LLC | $15.16 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherrie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.